- Home
- SCNI vs NCNA Comparison
SCNI vs NCNA Comparison
Compare SCNI & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- NCNA
- Stock Information
- Founded
- SCNI 2003
- NCNA 1997
- Country
- SCNI Israel
- NCNA United Kingdom
- Employees
- SCNI N/A
- NCNA N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- SCNI Health Care
- NCNA Health Care
- Exchange
- SCNI Nasdaq
- NCNA Nasdaq
- Market Cap
- SCNI 2.8M
- NCNA 3.4M
- IPO Year
- SCNI N/A
- NCNA 2017
- Fundamental
- Price
- SCNI $2.85
- NCNA $0.97
- Analyst Decision
- SCNI
- NCNA Buy
- Analyst Count
- SCNI 0
- NCNA 2
- Target Price
- SCNI N/A
- NCNA $25.00
- AVG Volume (30 Days)
- SCNI 10.1K
- NCNA 118.8K
- Earning Date
- SCNI 05-14-2025
- NCNA 05-15-2025
- Dividend Yield
- SCNI N/A
- NCNA N/A
- EPS Growth
- SCNI N/A
- NCNA N/A
- EPS
- SCNI 8.20
- NCNA N/A
- Revenue
- SCNI $452,000.00
- NCNA N/A
- Revenue This Year
- SCNI N/A
- NCNA N/A
- Revenue Next Year
- SCNI N/A
- NCNA N/A
- P/E Ratio
- SCNI $0.34
- NCNA N/A
- Revenue Growth
- SCNI N/A
- NCNA N/A
- 52 Week Low
- SCNI $2.23
- NCNA $0.69
- 52 Week High
- SCNI $8.92
- NCNA $10.79
- Technical
- Relative Strength Index (RSI)
- SCNI 34.84
- NCNA 48.38
- Support Level
- SCNI $2.64
- NCNA $0.81
- Resistance Level
- SCNI $2.86
- NCNA $1.34
- Average True Range (ATR)
- SCNI 0.25
- NCNA 0.14
- MACD
- SCNI -0.06
- NCNA 0.02
- Stochastic Oscillator
- SCNI 35.93
- NCNA 29.20
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.